Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Completes Acquisition of CombinatoRx from Zalicus

Published: Monday, June 02, 2014
Last Updated: Monday, June 02, 2014
Bookmark and Share
Acquisition of revenue generating and complementary business establishes Horizon’s headquarters in North America.

Horizon Discovery Group plc announces it has completed the acquisition of the CombinatoRx service business (known as the combination high throughput screening (cHTS) business) and related assets from Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, for £4.74m ($8.0m USD). 

The new business will become Horizon CombinatoRx Incorporated, a wholly owned subsidiary of Horizon. Horizon CombinatoRx, Inc. will be located in 23,000 sq. ft. of laboratory and office space in Kendall Square, Cambridge, MA, providing a base for future growth of Horizon business operations in North America. 

The acquisition provides access to the unique cHTS platform and Chalice™ analytics software, which enables the screening and analysis of thousands of complementary drug combinations.  The platform will be combined with Horizon’s GENESIS™ (rAAV, CRISPR & ZFN) gene editing platform and X-MAN™ isogenic cell line technology to be able to offer services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries. 

The assets acquired by Horizon, developed through a cumulative R&D investment of over $30 million, include:

• Two fully integrated robotic screening platforms optimized for combination screening
• Outstanding customer contracts
• The Chalice informatics platform
• A highly characterized library of approximately 800 cell lines
• An extensive compound and chemical probe library

Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc  commented: “The acquisition of the CombinatoRx service business not only gives Horizon a revenue generating, complementary business that has generated over $100 million of historical service revenue, but establishes Horizon in the heart of our key customer base in the East coast of the US. We look forward to unlocking the potential of the CombinatoRx business and integrating our own platform, which we believe will offer a truly unique set of services and capabilities to our customers.

“We are delighted to have completed this acquisition, within two months of our IPO, in line with the strategy outlined at our listing.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Discovery Secures Exclusive License from Case Western University to Panel of 35 Endogenously-Tagged Human Isogenic Cell Lines
Horizon Discovery has announced it has secured worldwide exclusive rights to a panel of new human isogenic cell models developed by Dr. Zhenghe Wang, Assistant Professor of Genetics at Case Western Reserve University School of Medicine.
Thursday, December 09, 2010
Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino
License relates to the use of human isogenic cell-lines in predicting the response of drugs targeted at the genetic make-up of individual cancer patients.
Tuesday, August 11, 2009
The X-MAN Steps-Out: Horizon Discovery Sign Screening and License Agreements with Agios Pharmaceuticals
Horizon Discovery (Horizon) today announced it has signed two commercial agreements with a ground-breaking U.S. cancer start-up; Agios Pharmaceuticals (Agios), relating to its X-MAN technology.
Wednesday, October 01, 2008
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Brazilian Zika Virus Strain Causes Birth Defects in Experimental Models
First direct experimental proof of causal effect, researchers say.
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!